

Cytori Therapeutics

Pharma & biotech
2 October 2015

Scleroderma therapy efficacy maintained

Recent data suggest the therapeutic benefits following a single administration of Cytori's ADRCs can persist for at least one year in patients with scleroderma-associated impaired hand function (SAIHF). Pivotal studies in SAIHF and urinary incontinence are underway.

Scleradec-I therapy benefit sustained at 12 months

12-month follow-up data from the open-label Scleradec-I study assessing a single administration of Cytori Cell Therapy (ECCS-50) in 12 patients with SAIHF were recently published in [Rheumatology](#). Hand function, as measured through the Cochin, and quality of life, determined using the Scleroderma Health Activity Questionnaire, improved from baseline by 51.3% and 46.8%, respectively, at 12 months ($p \leq 0.001$ for both). The Visual Analogue Scale for hand pain also showed a reduction vs baseline, nearing significance ($p=0.052$). This builds on previously reported six-month data showing improvements across multiple indicators.

US pivotal scleroderma study underway

Cytori started the 80-patient pivotal [Phase III study](#) assessing ECCS-50 in patients with SAIHF in July 2015. The firm received clearance from the US FDA to allow the cell therapy processing device used in this study to include technological updates that improve ECCS-50 manufacturing efficiency. The primary endpoint is the six-month change in the Cochin score (12-month change is a secondary endpoint) and recruitment is expected to take one year. Top-line data are expected in H217. A European randomized Phase III trial (Scleradec II) should begin in Q415.

Enrolment started in Japanese Phase III UIT study

In September, Cytori, in collaboration with Nagoya University, started the ADRESU Phase III Japanese trial studying Cytori Cell Therapy (ECCI-50) in men with urinary incontinence after prostatic surgery. The 45-patient study is substantially funded by the Japanese health ministry, and the primary endpoint will be the number of patients who experience reduction of urinary leakage volume 52 weeks after treatment. Cytori will seek approval in this indication if results are positive.

Valuation: EV of \$46m, upside driven by future data

After raising \$2.2m (net) in August 2015 and given an H115 operating cash burn rate of \$9.8m, we estimate Q315 net cash at c \$5.0m. Given \$16.2m long-term debt at end Q215, we estimate gross cash (c \$21m) should last into Q316, likely including the readout of the ongoing 90-patient [Phase II](#) knee osteoarthritis study.

Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/13	7.1	(26.2)	(0.39)	0.0	N/A	N/A
12/14	5.0	(37.4)	(0.48)	0.0	N/A	N/A
12/15e	14.15	(30.0)	(0.23)	0.0	N/A	N/A
12/16e	28.58	(18.25)	(0.12)	0.0	N/A	N/A

Source: Bloomberg

Price **\$0.32**
Market cap **\$51m**

Share price graph



Share details

Code	CYTX
Listing	NASDAQ
Shares in issue	158.5m

Business description

Cytori is a US company focused on the development of patient-derived (autologous) adipose-derived regenerative cells (ADRCs) for the treatment of impaired hand function in scleroderma, osteoarthritis of the knee, and radiation exposure-associated deep thermal burns.

Bull

- Cytori's lead programme (scleroderma) recently began Phase III trials in an orphan indication with significant sales potential.
- Cytori's approach requires no off-site processing, so generated ADRCs can be administered to the patient on the same day of extraction.
- Current commercial product contract revenue (including Celution and consumables) provide meaningful cash burn offset.

Bear

- Financing or partnership likely required by H216 to continue scleroderma studies and/or advance osteoarthritis programme to Phase III.
- Several competitors emerging in cell/regenerative therapy area, also targeting inflammatory diseases.
- Osteoarthritis is a relatively high-risk indication for new product or drug development.

Analysts

Pooya Hemami, CFA	+1 646 653 7026
Christian Glennie	+44 (0)20 3077 5727
healthcare@edisongroup.com	

QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Cytori Therapeutics is a research client of Edison Investment Research Limited

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Cytoti Therapeutics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2015]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.